Actualités

DaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attributed the quarter’s outperformance to balanced gains across treatment volume, revenue per treatment, and cost management, aided by productivity improvements and favorable patient outcomes. CEO Javier Rodriguez highlighted the continued momentum of the company’s Integrated Kidney Care (IKC) business, which delivered year-over-year improvement

HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.